AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.460
-0.010 (-0.29%)
Mar 13, 2026, 3:45 PM EDT - Market open
AbCellera Biologics Revenue
In the year 2025, AbCellera Biologics had annual revenue of $75.13M with 160.56% growth. AbCellera Biologics had revenue of $44.85M in the quarter ending December 31, 2025, with 788.18% growth.
Revenue (ttm)
$75.13M
Revenue Growth
+160.56%
P/S Ratio
13.96
Revenue / Employee
$133,680
Employees
562
Market Cap
1.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75.13M | 46.30M | 160.56% |
| Dec 31, 2024 | 28.83M | -9.19M | -24.17% |
| Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
| Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
| Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 362.27M |
| Geron | 183.88M |
| Septerna | 45.95M |
| Inventiva | 19.93M |
| uniQure | 16.10M |
| Precigen | 6.31M |
| Aktis Oncology | 5.56M |
| Inhibrx Biosciences | 1.40M |
ABCL News
- 6 days ago - AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 16 days ago - AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - AbCellera Reports Full Year 2025 Business Results - Business Wire
- 4 weeks ago - AbCellera to Present at Upcoming Investor Conferences in March and April 2026 - Business Wire
- 7 weeks ago - AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - Business Wire
- 2 months ago - AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - Business Wire
- 3 months ago - AbCellera and Bruker Reach Global Settlement of Patent Litigation - Business Wire